PortalPublikationenPSMA PET-directed surgical metastasis-directed therapy in me...

PSMA PET-directed surgical metastasis-directed therapy in metachronous prostate cancer

Standard

PSMA PET-directed surgical metastasis-directed therapy in metachronous prostate cancer. / Ambrosini, Francesca; Koehler, Daniel; Ghadban, Tarik; Jacobsen, Frank; Knipper, Sophie; von Amsberg, Gunhild; Steuber, Thomas; Maurer, Tobias.

in: CENT EUR J UROL, Jahrgang 76, Nr. 3, 2023, S. 182-185.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Case Report › Forschung › Begutachtung

Harvard

Ambrosini, F, Koehler, D, Ghadban, T, Jacobsen, F, Knipper, S, von Amsberg, G, Steuber, T & Maurer, T 2023, 'PSMA PET-directed surgical metastasis-directed therapy in metachronous prostate cancer', CENT EUR J UROL, Jg. 76, Nr. 3, S. 182-185. https://doi.org/10.5173/ceju.2023.69

APA

Ambrosini, F., Koehler, D., Ghadban, T., Jacobsen, F., Knipper, S., von Amsberg, G., Steuber, T., & Maurer, T. (2023). PSMA PET-directed surgical metastasis-directed therapy in metachronous prostate cancer. CENT EUR J UROL, 76(3), 182-185. https://doi.org/10.5173/ceju.2023.69

Vancouver

Ambrosini F, Koehler D, Ghadban T, Jacobsen F, Knipper S, von Amsberg G et al. PSMA PET-directed surgical metastasis-directed therapy in metachronous prostate cancer. CENT EUR J UROL. 2023;76(3):182-185. https://doi.org/10.5173/ceju.2023.69

Bibtex

@article{403f1101a9cd4abdb3947a8498073d97,
title = "PSMA PET-directed surgical metastasis-directed therapy in metachronous prostate cancer",
abstract = "We present the case of a patient who underwent an open radical prostatectomy with pelvic lymph node dissection (Gleason 4+3, pT3a pN1 R0) in March 2017. In November 2020, prostate-specific membrane antigen (PSMA)-radioguided salvage lymph node dissection was planned due to a single left para-rectal lymph node at a [68Ga] Ga-PSMA-I&T PET. In January 2022, the [68Ga] Ga-PSMA-I&T PET showed an isolated liver lesion. Biopsy confirmed prostate adenocarcinoma. A liver segmentectomy was performed. A complete biochemical response was reported until the last follow-up (December 2022). Prostate-specific membrane antigen positron emission tomography (PSMA PET)-directed metastasis-directed therapy may be an effective treatment in selected cases, allowing a benefit in the oncological outcome.",
author = "Francesca Ambrosini and Daniel Koehler and Tarik Ghadban and Frank Jacobsen and Sophie Knipper and {von Amsberg}, Gunhild and Thomas Steuber and Tobias Maurer",
note = "Copyright by Polish Urological Association.",
year = "2023",
doi = "10.5173/ceju.2023.69",
language = "English",
volume = "76",
pages = "182--185",
journal = "CENT EUR J UROL",
issn = "2080-4806",
publisher = "Panstwowy Zaklad Wydawnictw Lekarskich",
number = "3",

}

RIS

TY - JOUR

T1 - PSMA PET-directed surgical metastasis-directed therapy in metachronous prostate cancer

AU - Ambrosini, Francesca

AU - Koehler, Daniel

AU - Ghadban, Tarik

AU - Jacobsen, Frank

AU - Knipper, Sophie

AU - von Amsberg, Gunhild

AU - Steuber, Thomas

AU - Maurer, Tobias

N1 - Copyright by Polish Urological Association.

PY - 2023

Y1 - 2023

N2 - We present the case of a patient who underwent an open radical prostatectomy with pelvic lymph node dissection (Gleason 4+3, pT3a pN1 R0) in March 2017. In November 2020, prostate-specific membrane antigen (PSMA)-radioguided salvage lymph node dissection was planned due to a single left para-rectal lymph node at a [68Ga] Ga-PSMA-I&T PET. In January 2022, the [68Ga] Ga-PSMA-I&T PET showed an isolated liver lesion. Biopsy confirmed prostate adenocarcinoma. A liver segmentectomy was performed. A complete biochemical response was reported until the last follow-up (December 2022). Prostate-specific membrane antigen positron emission tomography (PSMA PET)-directed metastasis-directed therapy may be an effective treatment in selected cases, allowing a benefit in the oncological outcome.

AB - We present the case of a patient who underwent an open radical prostatectomy with pelvic lymph node dissection (Gleason 4+3, pT3a pN1 R0) in March 2017. In November 2020, prostate-specific membrane antigen (PSMA)-radioguided salvage lymph node dissection was planned due to a single left para-rectal lymph node at a [68Ga] Ga-PSMA-I&T PET. In January 2022, the [68Ga] Ga-PSMA-I&T PET showed an isolated liver lesion. Biopsy confirmed prostate adenocarcinoma. A liver segmentectomy was performed. A complete biochemical response was reported until the last follow-up (December 2022). Prostate-specific membrane antigen positron emission tomography (PSMA PET)-directed metastasis-directed therapy may be an effective treatment in selected cases, allowing a benefit in the oncological outcome.

U2 - 10.5173/ceju.2023.69

DO - 10.5173/ceju.2023.69

M3 - Case report

C2 - 38045775

VL - 76

SP - 182

EP - 185

JO - CENT EUR J UROL

JF - CENT EUR J UROL

SN - 2080-4806

IS - 3

ER -